Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

Eli Lilly (LLY) closed the most recent trading day at $825.91, moving +0.41% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.55%. Meanwhile, the ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued an opinion that does not recommend Eli Lilly (LLY) and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other billionaire Ken Fisher’s top growth stock picks. “Who am I to tell you anything ...

Weinand recommends investing in UnitedHealth Group (UNH), as the company is trading at an attractive P/E ratio. He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...